

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account No.: 50-1212/UTSG:239.

Reconsideration of the application in view of the following amendment and remarks is respectfully requested.

AMENDMENT

Please make the following amendments.

In the Specification:

On page 15 please replace the phrase "FIG. 17" with "FIG. 17A-17C".

On page 15 please replace the phrase "FIG. 18" with "FIG. 18A-18B".

In the Claims:

Please amend claims to read as follows.

18. (Amended) The method of claim 17, wherein the chemotherapeutic drug comprises an alkylating agent.

34. (Amended) A method for inhibiting the cell cycle progression of a mammalian cancer cell comprising contacting the cell with an amount of troglitazone and a chemotherapeutic drug effective to inhibit the cell cycle progression of the cell.

REMARKS

Claims 1-46 are pending. Claims 18 and 34 are amended herein. The amendment to claim 18 is to correct a typographical error in the word "alkylating". The amendment to claim 34